Sangamo Therapeutics, Inc. announced the appointment of Rob Schott as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo’s Chief Executive Officer. Sangamo also announced that, effective January 1, 2021, Jason Fontenot, PhD, has been promoted to Chief Scientific Officer. Dr. Fontenot has served as Sangamo’s Head of Cell Therapy since March 2019 and as the acting Interim Head of Research since June 2020. Prior to joining Sangamo, Dr. Schott served as the Chief Medical Officer at Chorus, an autonomous early-phase development engine inside of Eli Lilly, where he oversaw teams working to expand Eli Lilly’s pipeline.